Rocio Carbonero-Garcia
Elite in Pancreatic Islet Cell Tumor

Rocio Carbonero-Garcia

Complejo Hospitalario Universitario De Santiago
Santiago De Compostela, GA, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Pancreatic Islet Cell Tumor
Complejo Hospitalario Universitario De Santiago
Santiago De Compostela, GA, ES 
OverviewLocationsClinical Research

Overview

Rocio Carbonero-Garcia practices in Santiago De Compostela, Spain. Ms. Carbonero-Garcia and is rated as an Elite expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Colorectal Cancer, Tissue Biopsy, and Appendectomy.

Her clinical research consists of co-authoring 187 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles and participated in 3 clinical trials in the study of Pancreatic Islet Cell Tumor.

Gender
Female

Locations

Complejo Hospitalario Universitario de Santiago
Santiago De Compostela, GA, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial)
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial)
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation
Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation
Enrollment Status: Unknown
Publish Date: February 26, 2021
Intervention Type: Drug
Study Drugs: Personalised Treatment, Treatment Chosen per Investigator´s Judge
Study Phase: Phase 2
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Enrollment Status: Completed
Publish Date: March 24, 2020
View 5 Less Clinical Trials

187 Total Publications

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: December 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Carbonero-Garcia's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile